← Leaderboards
Phillip G Febbo
Dana-Farber Cancer Institute
$3,708,103
Attributed
$4,958,840
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,958,840 · 5
By mechanism
R01$2,159,131 · 2
U01$1,128,425 · 1
RC1$996,908 · 1
K23$674,376 · 1
Top collaborators
- Martin Edwin Gleave2 shared
- Susan Halabi2 shared
- Peter S Nelson2 shared
Most similar at Dana-Farber Cancer Institute
Same institution · by research overlap
- William G Kaelin$28,163,102
- James Brugarolas$10,657,328
- Othon Iliopoulos$11,620,320
- Myles A Brown$19,328,495
- Jonathan A Fletcher$3,049,199
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorPathway InteractionsBasePhenotypeMolecularAndrogensMalignant Neoplasm Of ProstateGrantClinical TrialsBiologyResistanceResponseGeneticSamplingSignal TransductionProstateResistance MechanismOncogenicMetastatic Prostate CancerDocetaxelGene ExpressionCancer TherapyCombined Modality TherapyClinical Research
Grant awards (16)
Validation of prognostic and pathway signatures in lethal prostate cancer$525,083
U01 · FY2012 · CA · contact PI
Validation of prognostic and pathway signatures in lethal prostate cancer$603,342
U01 · FY2011 · CA · contact PI
Predictive Markers in Metastatic Renal Cancer$602,629
R01 · FY2011 · CA · contact PI
mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance$303,344
R01 · FY2011 · CA · contact PI
Mechanism-based Classification and Targeting of Castration-Resistant Prostate Can$496,917
RC1 · FY2010 · CA
mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance$312,725
R01 · FY2010 · CA · contact PI
Mechanism-based Classification and Targeting of Castration-Resistant Prostate Can$499,991
RC1 · FY2009 · CA
mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance$308,811
R01 · FY2009 · CA · contact PI
mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance$308,811
R01 · FY2008 · CA · contact PI
mTOR Therapy in Prostate Cancer: Signatures of Response and Biology of Resistance$322,811
R01 · FY2007 · CA · contact PI
Expression Analysis of Prostate Cancer$68,005
K23 · FY2006 · CA · contact PI
Expression Analysis of Prostate Cancer$131,261
K23 · FY2005 · CA
Expression Analysis of Prostate Cancer$135,837
K23 · FY2004 · CA
Expression Analysis of Prostate Cancer$135,837
K23 · FY2003 · CA
Expression Analysis of Prostate Cancer$67,919
K23 · FY2002 · CA
Expression Analysis of Prostate Cancer$135,517
K23 · FY2001 · CA